Tag: Ardigen

Ardigen, a global leader in artificial intelligence & bioinformatics for precision medicine, announces its collaboration with the DKFZ research groups, led by Prof. Michael Platten/ Dr. Edward Green, regarding safety assessments of TCR based therapies (TCR-Ts). As a part of […]

  October 25, 2022 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in […]

  March 24, 2022 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Lukasz Dutkiewicz, PhD has joined the company as Business Development Director of the Digital CRO division. He brings extensive knowledge […]

Krakow, Poland, 04.11.2021. Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, announced that another distinguished scientist joined the company’s Scientific Advisory Board. Prof. Olivera Finn will support Ardigen’s work on AI-driven technology […]

Ardigen received funding for development of AI-powered Microbiome Platform that will improve prediction of cancer therapies efficacy. Krakow, Poland, 25.10.2021. Ardigen- the world-leading company that utilizes Artificial Intelligence (AI) for drug discovery, has signed an agreement with the Polish National […]

September 7, 2021 – Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Dr. Aleksandra Walczak joined the company’s Scientific Council. With a PhD in physical sciences and her […]